ASL 分数肿瘤负荷鉴别脑转移瘤复发与放射性坏死
本研究回顾性纳入 86 例患者共 102 个接受 SRS 后的脑转移瘤,以组织病理或临床-影像随访为参考标准,评估 ASL 衍生的分数肿瘤负荷鉴别肿瘤复发与放射性坏死的效能。结果显示归一化 FTB-high AUC 为 0.81,敏感度 0.79,特异度 0.74,与常规 CBF 指标相当并显著优于 delta T1。
要点
- 归一化 FTB-high 可较好区分复发与放射性坏死,NPV 达 0.88。
- FTB-high 每增加 10%,肿瘤概率对应增加 1.62 倍。
- 体素级灌注指标对放疗后反应评估具有可解读的临床价值。
核心结论
- ASL 衍生的归一化 FTB-high 对 SRS 后脑转移瘤复发与放射性坏死具有良好鉴别能力。
- 归一化 FTB-high 诊断效能与常规 CBF 指标相当,并显著优于 delta T1。
- FTB-high 与肿瘤概率呈单调正相关,适合用于放疗后疗效评估。
研究设计与样本
- 回顾性研究,纳入 86 例患者共 102 个 SRS 后脑转移瘤。
- 病灶构成包括 68 个放射性坏死与 34 个肿瘤复发。
- 参考标准为组织病理学或临床-影像随访结果。
- 主要终点为 FTB-high 体素百分比(绝对值与归一化值)。
- 绝对 CBF 阈值预先设定为 ≤50 与 ≥80 mL/100 g/min,归一化阈值 ≤1.0 与 ≥1.4。
关键影像表现/征象
- FTB 是基于体素水平的灌注指标,可显示病灶内灌注异质性。
诊断标准与关键数值
- 归一化 FTB-high 的 AUC 为 0.81(95% CI 0.71-0.90)。
- 归一化 FTB-high 的敏感度为 0.79(95% CI 0.63-0.94),特异度为 0.74(95% CI 0.61-0.86)。
- 归一化 FTB-high 的 PPV 为 0.60(95% CI 0.43-0.77),NPV 为 0.88(95% CI 0.77-0.96)。
- 绝对 FTB-high 的 AUC 为 0.75(95% CI 0.66-0.84),与归一化指标差异无统计学意义(P = 0.22)。
- FTB-high 每增加 10%,肿瘤概率的 OR 为 1.62(95% CI 1.33-2.38;P = 0.001)。
临床应用与阅片要点
- 体素级 FTB-high 可作为 SRS 后复发与坏死的影像学生物标志物。
- ASL 无需对比剂,适合用于脑转移瘤放疗后随访灌注评估。
局限性
- 研究为回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Differentiating recurrent tumor from radiation necrosis after stereotactic radiosurgery remains a challenge with conventional MRI. Fractional tumor burden, a voxel-level perfusion biomarker originally developed using DSC-MRI, characterizes intralesional perfusion heterogeneity and has demonstrated good performance and improved interrater agreement in diagnostic interpretations over conventional perfusion metrics. We evaluated arterial spin labeling-derived fractional tumor burden for distinguishing tumor recurrence from radiation necrosis in treated brain metastases.
MATERIALS AND METHODS: This retrospective study included 86 patients with 102 brain metastases (68 radiation necrosis, 34 tumor) evaluated with arterial spin labeling-MRI after stereotactic radiosurgery. Ground truth was based on histopathology or clinico-radiologic follow-up. The primary endpoint was fractional tumor burden-high voxel percentage (absolute and normalized). Secondary endpoints included fractional tumor burden-low, mean CBF, maximum CBF, and delta T1. Absolute CBF thresholds of ≤50 and ≥80 mL/100 g/min and normalized thresholds of ≤1.0 and ≥1.4 were defined a priori from prior histopathology-informed data. Diagnostic performance was assessed by receiver operating characteristic analysis and DeLong testing. Between-group comparisons used Mann-Whitney U tests; generalized linear mixed-effects models assessed logistic regression.
RESULTS: Normalized fractional tumor burden-high demonstrated good discrimination of tumor from radiation necrosis, with area under the curve 0.81 (95% CI 0.71-0.90), sensitivity 0.79 (95% CI 0.63-0.94), specificity 0.74 (95% CI 0.61-0.86), PPV 0.60 (95% CI 0.43-0.77), and NPV 0.88 (95% CI 0.77-0.96), numerically outperforming absolute fractional tumor burden-high (area under the curve 0.75; 95% CI 0.66-0.84), although the difference was not significant (P = 0.22). Secondary arterial spin labeling-derived metrics demonstrated comparable performance (area under the curves = 0.79-0.83). Normalized fractional tumor burden-high significantly outperformed delta T1 (change in area under the curve = 0.19; 95% CI 0.05-0.31; P = 0.004). Logistic regression confirmed a monotonic association between normalized fractional tumor burden-high and tumor probability (OR = 1.62 per 10% increase; 95% CI 1.33-2.38; P = 0.001).
CONCLUSIONS: Arterial spin labeling-derived fractional tumor burden-high provides good lesion-level differentiation between recurrent brain metastases and radiation necrosis after stereotactic radiosurgery, performing comparably to conventional CBF metrics. The voxel-level approach offers a clinically interpretable perfusion biomarker suitable for post-treatment response assessment.
引用
- Christodoulou, Rahimy, Pollom, et al. Arterial Spin Labeling-Derived Fractional Tumor Burden as a Primary Biomarker for Differentiating Recurrent Tumor from Radiation Necrosis After Stereotactic Radiosurgery. AJNR Am J Neuroradiol. 2026. PMID: 42557018. doi:10.3174/ajnr.A9569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。